Company Overview

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics. The company operates within the biotechnology and oncology drug development industries, with an emphasis on therapies designed to address mechanisms of cancer progression and treatment resistance. Its activities are primarily centered on research and clinical development rather than commercial drug sales, and as of the latest public disclosures, the company does not generate product revenue.

The company’s strategy is built around developing small-molecule and targeted therapies intended to improve outcomes in difficult-to-treat cancers. Kairos Pharma positions itself by focusing on cancer biology pathways that are believed to contribute to tumor growth and recurrence, which management believes are insufficiently addressed by existing treatments. The company was founded in 2013 and has since evolved from early-stage research into a publicly traded entity following its listing on the Nasdaq Capital Market under the ticker KAPA, enabling expanded access to capital to fund clinical development.

Business Operations

Kairos Pharma’s operations are primarily organized around its oncology drug development programs, which include preclinical research and clinical trials for its proprietary therapeutic candidates. The company generates no meaningful operating revenue and instead relies on equity financing and other capital-raising activities to fund research, development, and general corporate operations. Its core assets consist of intellectual property, drug candidates, and regulatory data related to its oncology pipeline.

Operationally, the company conducts research through a combination of internal management and external partners, including contract research organizations that support preclinical studies and clinical trials. Kairos Pharma does not currently report distinct commercial operating segments, and its business is largely concentrated in advancing its lead product candidates through clinical milestones. Public filings indicate that the company has no material manufacturing operations of its own and no disclosed revenue-generating subsidiaries.

Strategic Position & Investments

Strategically, Kairos Pharma is focused on advancing its lead oncology candidates through clinical development, with the objective of demonstrating safety and efficacy sufficient to support later-stage trials or potential partnering opportunities. Growth initiatives center on expanding and validating its therapeutic pipeline, pursuing regulatory progress, and maintaining access to capital markets to support ongoing research and development.

The company’s investments are primarily directed toward clinical trials, intellectual property protection, and scientific personnel rather than acquisitions of operating businesses. As of the most recent public information, Kairos Pharma has not disclosed any major acquisitions or ownership stakes in revenue-generating portfolio companies. Its strategic emphasis remains on internal development of proprietary cancer therapies, with potential future collaborations or licensing arrangements dependent on clinical outcomes. Data on emerging technology investments beyond its core oncology focus is inconclusive based on available public sources.

Geographic Footprint

Kairos Pharma is headquartered in the United States, with corporate offices located in California. Its operational footprint is relatively limited, reflecting its status as a clinical-stage biotechnology company, and its activities are primarily concentrated in North America.

Internationally, the company’s presence is indirect and largely tied to the use of global contract research organizations and clinical trial sites, rather than owned facilities or subsidiaries. There is no indication from public disclosures that Kairos Pharma maintains significant standalone operations, manufacturing facilities, or commercial infrastructure outside the United States, though its clinical and regulatory activities may involve multiple countries as trials progress.

Leadership & Governance

Kairos Pharma was founded by physician-scientists with backgrounds in oncology research, and its leadership emphasizes a science-driven approach to drug development and disciplined capital allocation. The company’s governance structure follows typical U.S. public company standards, with oversight provided by a board of directors and executive management responsible for strategy execution and regulatory compliance.

Key members of the executive leadership team include:

• John Yu, M.D. – Founder and Chief Executive Officer
• Steven Kilmer – Chief Financial Officer

Public statements and regulatory filings indicate that management’s strategic vision centers on advancing differentiated cancer therapies through clinical validation while managing development risk and preserving shareholder capital. Information on additional executive roles beyond those listed is limited, and further details are inconclusive based on available public sources.